Vicore Pharma announces the Nomination Committee for the 2020 Annual General Meeting
Gothenburg, October 3, 2019 – Vicore Pharma Holding AB (publ) has appointed the Nomination Committee for the 2020 Annual General Meeting. The three largest shareholders as of August 31, 2019 have been offered to appoint a member to the Nomination Committee each, in accordance with the decision taken at the Annual General Meeting on May 15, 2019.
The Nomination Committee consists of Staffan Lindstrand, appointed by HealthCap VII L.P., Göran Wessman, appointed by Protem Wessman AB and Evert Carlsson appointed by Swedbank Robur. Vicore Pharma’s chairman, Leif Darner, is also a member and acts as the convener of the Nomination Committee.
The task of the Nomination Committee is to prepare and present proposals for the number of Board members to be elected by the AGM, the election of a Chairman and other members of the Board, board fees and, if any, remuneration for committee work, election of a Chairman to the Annual General Meeting, election of auditors (if applicable) and auditors fees (if applicable) and proposals for rules for the appointment of a nomination committee for the Annual General Meeting 2021.
The Annual General Meeting of Vicore Pharma Holding AB (publ) will take place on May 20, 2020. Shareholders who wish to submit their comments or submit proposals to the Nomination Committee may do so by March 20, 2020 by email to info@vicorepharma.com or by letter to Vicore Pharma Holding AB (publ), Kronhusgatan 11, 411 05 Gothenburg. The Nomination Committee's proposal will be presented in the notice convening the AGM and on the company's website.
For further information, please contact:
Leif Darner, Chairman of the Board, tel: +46 705 79 04 62, leif.darner@vicorepharma.com
About Vicore Pharma Holding AB (publ)
Vicore Pharma is a Swedish rare disease pharmaceutical company focused on interstitial lung diseases and related indications. The company currently has two drug development programs, VP01 and VP02.
VP01 aims to develop the substance C21 for the treatment of idiopathic pulmonary fibrosis (“IPF”) and diffuse systemic sclerosis (“dSSc”). VP02 is based on a new formulation and delivery route of an existing immunomodulatory compound (an “IMiD”). VP02 focuses on the underlying disease and the severe cough associated with IPF. VP01 and VP02 are also being actively evaluated for other indications within the field of interstitial lung diseases which has a significant high unmet need. The VP01 Phase IIa studies in IPF and dSSc patients are expected to be initiated during the second half of 2019. VP02 is entering a phase of optimization of formulation before local tolerability studies will commence. The first clinical studies with VP02 are expected to start in 2020.
The company's shares (VICO) are listed on Nasdaq Stockholm’s main market. For more information, see www.vicorepharma.com.